Adaptimmune Therapeutics PLC SEC filings ADAPY

Adaptimmune Therapeutics PLC has 808 filings in SEC EDGAR's recent list, going back to Oct 2, 2014. Its latest annual report, Form ARS, was filed on Apr 25, 2025 for the period ended Dec 31, 2024. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2025, covering the quarter ended Jun 30, 2025. The most recent current report (Form 8-K) was filed on Oct 20, 2025 (listing notice, regulation fd disclosure). The company's fiscal year ends on December 31.

Adaptimmune Therapeutics PLC SEC filings
Form Description Filed Period
RW Filing Apr 22, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Feb 17, 2026 —
EFFECT Filing Nov 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Nov 14, 2025 —
424B3 Prospectus Nov 13, 2025 —
15-12G Deregistration Nov 13, 2025 —
S-8 POS Filing Oct 28, 2025 —
S-8 POS Filing Oct 28, 2025 —
S-8 POS Filing Oct 28, 2025 —
POS AM Filing Oct 28, 2025 —
25 Form 25 Oct 28, 2025 —
8-K Current report
Listing notice, Regulation FD disclosure
Oct 20, 2025 Oct 15, 2025
3 Initial insider ownership Oct 8, 2025 Sep 10, 2025
8-K Current report
Listing notice
Sep 26, 2025 Sep 22, 2025
8-K Current report
Listing notice
Sep 12, 2025 Sep 11, 2025
8-K Current report
Officer or director change
Sep 8, 2025 Sep 6, 2025
4 Insider transaction Sep 3, 2025 Sep 2, 2025
144 Notice of proposed sale Sep 2, 2025 —
4 Insider transaction Aug 29, 2025 Aug 28, 2025
144 Notice of proposed sale Aug 29, 2025 —
8-K Current report
Officer or director change
Aug 29, 2025 Aug 29, 2025
4 Insider transaction Aug 19, 2025 Aug 15, 2025
SCHEDULE 13D/A Amended ownership over 5% (active) Aug 19, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 19, 2025 —
8-K Current report
Officer or director change
Aug 15, 2025 Aug 15, 2025
144 Notice of proposed sale Aug 15, 2025 —
144 Notice of proposed sale Aug 15, 2025 —
8-K Current report
Listing notice
Aug 14, 2025 Aug 14, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 13, 2025 —
10-Q Quarterly report Aug 13, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 13, 2025 Aug 13, 2025
8-K Current report
Officer or director change
Aug 7, 2025 Aug 7, 2025
8-K Current report
Agreement ended, Acquisition or sale of assets
Jul 31, 2025 Jul 31, 2025
4 Insider transaction Jul 30, 2025 Jul 28, 2025
8-K Current report
Material agreement, Exit or restructuring costs, Officer or director change, Regulation FD disclosure
Jul 28, 2025 Jul 27, 2025
8-K Current report
Other events
Jul 17, 2025 Jul 16, 2025
8-K Current report
Shareholder vote results
May 29, 2025 May 29, 2025
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2025 —
10-Q Quarterly report May 13, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 13, 2025 May 13, 2025
8-K Current report
Listing notice
May 1, 2025 May 1, 2025
ARS Annual report to shareholders Apr 25, 2025 Dec 31, 2024
DEF 14A Proxy statement Apr 25, 2025 May 29, 2025
S-3 Shelf registration Apr 18, 2025 —
PRE 14A Preliminary proxy statement Apr 15, 2025 May 29, 2025
8-K Current report
Officer or director change
Apr 14, 2025 Apr 14, 2025
10-K Annual report Mar 24, 2025 Dec 31, 2024
8-K Current report
Material agreement
Mar 24, 2025 Mar 24, 2025
8-K Current report
Results of operations, Regulation FD disclosure
Mar 20, 2025 Mar 20, 2025
4 Insider transaction Feb 20, 2025 Feb 20, 2025
4 Insider transaction Feb 20, 2025 Feb 20, 2025
4 Insider transaction Feb 20, 2025 Feb 20, 2025
4 Insider transaction Feb 20, 2025 Feb 20, 2025
4 Insider transaction Feb 20, 2025 Feb 20, 2025
4 Insider transaction Feb 20, 2025 Feb 20, 2025
SCHEDULE 13G Ownership over 5% (passive) Feb 14, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 12, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Feb 11, 2025 —
4 Insider transaction Jan 17, 2025 Jan 17, 2025
4 Insider transaction Jan 17, 2025 Jan 17, 2025
4 Insider transaction Jan 17, 2025 Jan 17, 2025
4 Insider transaction Jan 17, 2025 Jan 17, 2025
144 Notice of proposed sale Jan 17, 2025 —
144 Notice of proposed sale Jan 17, 2025 —
144 Notice of proposed sale Jan 17, 2025 —
144 Notice of proposed sale Jan 17, 2025 —
4 Insider transaction Jan 15, 2025 Jan 13, 2025
4 Insider transaction Jan 15, 2025 Jan 15, 2025
4 Insider transaction Jan 15, 2025 Jan 13, 2025
4 Insider transaction Jan 15, 2025 Jan 13, 2025
4 Insider transaction Jan 15, 2025 Jan 13, 2025
144 Notice of proposed sale Jan 15, 2025 —
144 Notice of proposed sale Jan 15, 2025 —
144 Notice of proposed sale Jan 15, 2025 —
144 Notice of proposed sale Jan 15, 2025 —
144 Notice of proposed sale Jan 15, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Jan 8, 2025 —
8-K Current report
Officer or director change, Other events
Dec 19, 2024 Dec 18, 2024
SCHEDULE 13G/A Amended ownership over 5% (passive) Dec 5, 2024 —
10-Q Quarterly report Nov 13, 2024 Sep 30, 2024
8-K Current report
Results of operations, Exit or restructuring costs
Nov 13, 2024 Nov 13, 2024
8-K Current report
Other events
Nov 13, 2024 Nov 13, 2024
SC 13G/A Amended ownership over 5% (passive) Nov 13, 2024 —
8-K Current report
Listing notice
Nov 1, 2024 Nov 1, 2024
8-K Current report
Material agreement
Sep 23, 2024 Sep 23, 2024
10-Q Quarterly report Aug 12, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 12, 2024 Aug 12, 2024
8-K Current report
Regulation FD disclosure, Other events
Aug 2, 2024 Aug 1, 2024
8-K Current report
Officer or director change
Jul 16, 2024 Jul 16, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jul 1, 2024 Jul 1, 2024
4 Insider transaction Jun 18, 2024 Jun 18, 2024
8-K Current report
Officer or director change
Jun 11, 2024 Jun 11, 2024
8-K Current report
Material agreement, Regulation FD disclosure
May 30, 2024 May 30, 2024
10-Q Quarterly report May 15, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 15, 2024 May 15, 2024
8-K Current report
Material agreement, New debt, Regulation FD disclosure
May 15, 2024 May 14, 2024
8-K Current report
Shareholder vote results
May 14, 2024 May 14, 2024
ARS Annual report to shareholders Apr 22, 2024 Dec 31, 2023
8-K Current report
Agreement ended
Apr 12, 2024 Apr 10, 2024
DEF 14A Proxy statement Apr 11, 2024 May 14, 2024
SC 13D/A Amended ownership over 5% (active) Apr 2, 2024 —
PRE 14A Preliminary proxy statement Apr 1, 2024 May 14, 2024
3 Initial insider ownership Mar 26, 2024 Mar 8, 2024
SC 13G/A Amended ownership over 5% (passive) Mar 26, 2024 —
4 Insider transaction Mar 18, 2024 Mar 18, 2024
10-K Annual report Mar 6, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 6, 2024 Mar 6, 2024
8-K Current report
Officer or director change
Feb 27, 2024 Feb 26, 2024
8-K Current report
Listing notice
Feb 16, 2024 Feb 16, 2024
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2024 —
8-K Current report
Other events
Jan 31, 2024 Jan 31, 2024
SC 13G Ownership over 5% (passive) Jan 30, 2024 —
SC 13G/A Amended ownership over 5% (passive) Jan 29, 2024 —
4 Insider transaction Jan 17, 2024 Jan 16, 2024
4 Insider transaction Jan 17, 2024 Jan 16, 2024
4 Insider transaction Jan 17, 2024 Jan 16, 2024
4 Insider transaction Jan 17, 2024 Jan 16, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 17, 2024 Jan 15, 2024
4 Insider transaction Jan 12, 2024 Jan 11, 2024
4 Insider transaction Jan 12, 2024 Jan 11, 2024
4 Insider transaction Jan 12, 2024 Jan 11, 2024
4 Insider transaction Jan 12, 2024 Jan 11, 2024
8-K Current report
Regulation FD disclosure
Jan 4, 2024 Jan 4, 2024
8-K Current report
Other events
Dec 6, 2023 Dec 6, 2023
S-8 Employee stock plan registration Nov 30, 2023 —
8-K Current report
Other events
Nov 14, 2023 Nov 14, 2023
10-Q Quarterly report Nov 8, 2023 Sep 30, 2023
SC 13G Ownership over 5% (passive) Nov 8, 2023 —
8-K Current report
Results of operations
Nov 8, 2023 Nov 8, 2023
8-K Current report
Officer or director change
Nov 3, 2023 Nov 1, 2023
3 Initial insider ownership Nov 1, 2023 Nov 1, 2023
8-K Current report
Regulation FD disclosure
Oct 31, 2023 Oct 31, 2023
4 Insider transaction Sep 1, 2023 Sep 1, 2023
8-K Current report
Listing notice
Aug 31, 2023 Aug 31, 2023
8-K/A Amended current report Aug 10, 2023 Jun 1, 2023
10-Q Quarterly report Aug 9, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 9, 2023 Aug 9, 2023
4 Insider transaction Aug 1, 2023 Aug 1, 2023
4 Insider transaction Jul 10, 2023 Jul 10, 2023
SC 13G/A Amended ownership over 5% (passive) Jul 10, 2023 —
4 Insider transaction Jul 5, 2023 Jul 5, 2023
4 Insider transaction Jul 5, 2023 Jul 5, 2023
4 Insider transaction Jul 5, 2023 Jul 5, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
4 Insider transaction Jul 3, 2023 Jul 3, 2023
S-8 POS Filing Jun 29, 2023 —
S-8 POS Filing Jun 29, 2023 —
8-K Current report
Officer or director change
Jun 29, 2023 Jun 29, 2023
4 Insider transaction Jun 27, 2023 Jun 27, 2023
4 Insider transaction Jun 1, 2023 Jun 1, 2023
3 Initial insider ownership Jun 1, 2023 Jun 1, 2023
3 Initial insider ownership Jun 1, 2023 Jun 1, 2023
3 Initial insider ownership Jun 1, 2023 Jun 1, 2023
8-K Current report
Acquisition or sale of assets, Officer or director change, Regulation FD disclosure
Jun 1, 2023 Jun 1, 2023
425 Filing May 30, 2023 —
8-K Current report
Shareholder vote results
May 30, 2023 May 30, 2023
425 Filing May 22, 2023 —
8-K Current report
Other events
May 22, 2023 May 22, 2023
8-K Current report
Shareholder vote results
May 16, 2023 May 16, 2023
10-Q Quarterly report May 12, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 12, 2023 May 12, 2023
EFFECT Filing Apr 20, 2023 —
424B3 Prospectus Apr 20, 2023 —
CORRESP Letter to the SEC Apr 18, 2023 —
S-4/A Filing Apr 18, 2023 —
DEF 14A Proxy statement Apr 13, 2023 —
8-K Current report
Material agreement, Regulation FD disclosure
Apr 11, 2023 Apr 6, 2023
UPLOAD Letter from the SEC Apr 6, 2023 —
S-4 Registration for a merger or exchange Apr 5, 2023 —
PRE 14A Preliminary proxy statement Apr 3, 2023 —
SC 13D/A Amended ownership over 5% (active) Mar 30, 2023 —
8-K Current report
Regulation FD disclosure
Mar 10, 2023 Mar 10, 2023
425 Filing Mar 9, 2023 —
425 Filing Mar 9, 2023 —
10-K Annual report Mar 6, 2023 Dec 31, 2022
8-K Current report
Agreement ended, Results of operations, Officer or director change
Mar 6, 2023 Mar 2, 2023
425 Filing Mar 6, 2023 —
8-K Current report
Material agreement, Regulation FD disclosure
Mar 6, 2023 Mar 5, 2023

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ADAPY (OTC)
Fiscal year ends
December 31
Incorporated in
United Kingdom
Headquarters
Abingdon, Oxfordshire
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1621227
Former names
Adaptimmune Ltd (until Mar 17, 2015)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.